Evaluating the virucidal efficacy of hydrogen peroxide vapour
Identifieur interne : 001795 ( Main/Merge ); précédent : 001794; suivant : 001796Evaluating the virucidal efficacy of hydrogen peroxide vapour
Auteurs : S. M. Goyal [États-Unis] ; Y. Chander [États-Unis] ; S. Yezli [Royaume-Uni] ; J. A. Otter [Royaume-Uni]Source :
- The Journal of hospital infection [ 0195-6701 ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Santé publique.
English descriptors
- KwdEn :
Abstract
Background: Surface contamination has been implicated in the transmission of certain viruses, and surface disinfection can be an effective measure to interrupt the spread of these agents. Aim: To evaluate the in-vitro efficacy of hydrogen peroxide vapour (HPV), a vapour-phase disinfection method, for the inactivation of a number of structurally distinct viruses of importance in the healthcare, veterinary and public sectors. The viruses studied were: feline calicivirus (FCV, a norovirus surrogate); human adenovirus type 1; transmissible gastroenteritis coronavirus of pigs (TGEV, a severe acute respiratory syndrome coronavirus [SARS-CoV] surrogate); avian influenza virus (AIV); and swine influenza virus (SwIV). Methods: The viruses were dried on stainless steel discs in 20- or 40-μL aliquots and exposed to HPV produced by a Clarus L generator (Bioquell, Horsham, PA, USA) in a 0.2-m3 environmental chamber. Three vaporized volumes of hydrogen peroxide were tested in triplicate for each virus: 25, 27 and 33 mL. Findings: No viable viruses were identified after HPV exposure at any of the vaporized volumes tested. HPV was virucidal (>4-log reduction) against FCV, adenovirus, TGEV and AIV at the lowest vaporized volume tested (25 mL). For SwIV, due to low virus titre on the control discs, >3.8-log reduction was shown for the 25-mL vaporized volume and >4-log reduction was shown for the 27-mL and 33-mL vaporized volumes. Conclusion: HPV was virucidal for structurally distinct viruses dried on surfaces, suggesting that HPV can be considered for the disinfection of virus-contaminated surfaces.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000009
- to stream PascalFrancis, to step Curation: 000978
- to stream PascalFrancis, to step Checkpoint: 000008
Links to Exploration step
Pascal:14-0118111Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evaluating the virucidal efficacy of hydrogen peroxide vapour</title>
<author><name sortKey="Goyal, S M" sort="Goyal, S M" uniqKey="Goyal S" first="S. M." last="Goyal">S. M. Goyal</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Veterinary Population Medicine, University of Minnesota</s1>
<s2>Saint Paul, MN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chander, Y" sort="Chander, Y" uniqKey="Chander Y" first="Y." last="Chander">Y. Chander</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Veterinary Population Medicine, University of Minnesota</s1>
<s2>Saint Paul, MN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yezli, S" sort="Yezli, S" uniqKey="Yezli S" first="S." last="Yezli">S. Yezli</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Bioquell UK Ltd</s1>
<s2>Andover</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Bioquell UK Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Otter, J A" sort="Otter, J A" uniqKey="Otter J" first="J. A." last="Otter">J. A. Otter</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Bioquell UK Ltd</s1>
<s2>Andover</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Bioquell UK Ltd</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Clinical Infection and Diagnostics Research (CIDR), Department of Infectious Diseases, King's College London School of Medicine and Guy's and St Thomas' NHS Foundation Trust</s1>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Centre for Clinical Infection and Diagnostics Research (CIDR), Department of Infectious Diseases, King's College London School of Medicine and Guy's and St Thomas' NHS Foundation Trust</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0118111</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0118111 INIST</idno>
<idno type="RBID">Pascal:14-0118111</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000009</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000978</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000008</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000008</idno>
<idno type="wicri:doubleKey">0195-6701:2014:Goyal S:evaluating:the:virucidal</idno>
<idno type="wicri:Area/Main/Merge">001795</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evaluating the virucidal efficacy of hydrogen peroxide vapour</title>
<author><name sortKey="Goyal, S M" sort="Goyal, S M" uniqKey="Goyal S" first="S. M." last="Goyal">S. M. Goyal</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Veterinary Population Medicine, University of Minnesota</s1>
<s2>Saint Paul, MN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chander, Y" sort="Chander, Y" uniqKey="Chander Y" first="Y." last="Chander">Y. Chander</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Veterinary Population Medicine, University of Minnesota</s1>
<s2>Saint Paul, MN</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yezli, S" sort="Yezli, S" uniqKey="Yezli S" first="S." last="Yezli">S. Yezli</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Bioquell UK Ltd</s1>
<s2>Andover</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Bioquell UK Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Otter, J A" sort="Otter, J A" uniqKey="Otter J" first="J. A." last="Otter">J. A. Otter</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Bioquell UK Ltd</s1>
<s2>Andover</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Bioquell UK Ltd</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Clinical Infection and Diagnostics Research (CIDR), Department of Infectious Diseases, King's College London School of Medicine and Guy's and St Thomas' NHS Foundation Trust</s1>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Centre for Clinical Infection and Diagnostics Research (CIDR), Department of Infectious Diseases, King's College London School of Medicine and Guy's and St Thomas' NHS Foundation Trust</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of hospital infection</title>
<title level="j" type="abbreviated">J. hosp. infect.</title>
<idno type="ISSN">0195-6701</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of hospital infection</title>
<title level="j" type="abbreviated">J. hosp. infect.</title>
<idno type="ISSN">0195-6701</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Decontamination</term>
<term>Disinfection</term>
<term>Feline calicivirus</term>
<term>Gastroenteritis</term>
<term>Human papillomavirus</term>
<term>Influenza</term>
<term>Norovirus</term>
<term>Peroxides Hydrogen</term>
<term>Public health</term>
<term>Severe acute respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Grippe</term>
<term>Gastroentérite</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Antiviral</term>
<term>Peroxyde Hydrogène</term>
<term>Désinfection</term>
<term>Décontamination</term>
<term>Papillomavirus humain</term>
<term>Calicivirus félin</term>
<term>Santé publique</term>
<term>Norovirus</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Surface contamination has been implicated in the transmission of certain viruses, and surface disinfection can be an effective measure to interrupt the spread of these agents. Aim: To evaluate the in-vitro efficacy of hydrogen peroxide vapour (HPV), a vapour-phase disinfection method, for the inactivation of a number of structurally distinct viruses of importance in the healthcare, veterinary and public sectors. The viruses studied were: feline calicivirus (FCV, a norovirus surrogate); human adenovirus type 1; transmissible gastroenteritis coronavirus of pigs (TGEV, a severe acute respiratory syndrome coronavirus [SARS-CoV] surrogate); avian influenza virus (AIV); and swine influenza virus (SwIV). Methods: The viruses were dried on stainless steel discs in 20- or 40-μL aliquots and exposed to HPV produced by a Clarus L generator (Bioquell, Horsham, PA, USA) in a 0.2-m<sup>3</sup>
environmental chamber. Three vaporized volumes of hydrogen peroxide were tested in triplicate for each virus: 25, 27 and 33 mL. Findings: No viable viruses were identified after HPV exposure at any of the vaporized volumes tested. HPV was virucidal (>4-log reduction) against FCV, adenovirus, TGEV and AIV at the lowest vaporized volume tested (25 mL). For SwIV, due to low virus titre on the control discs, >3.8-log reduction was shown for the 25-mL vaporized volume and >4-log reduction was shown for the 27-mL and 33-mL vaporized volumes. Conclusion: HPV was virucidal for structurally distinct viruses dried on surfaces, suggesting that HPV can be considered for the disinfection of virus-contaminated surfaces.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Minnesota</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Minnesota"><name sortKey="Goyal, S M" sort="Goyal, S M" uniqKey="Goyal S" first="S. M." last="Goyal">S. M. Goyal</name>
</region>
<name sortKey="Chander, Y" sort="Chander, Y" uniqKey="Chander Y" first="Y." last="Chander">Y. Chander</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Yezli, S" sort="Yezli, S" uniqKey="Yezli S" first="S." last="Yezli">S. Yezli</name>
</noRegion>
<name sortKey="Otter, J A" sort="Otter, J A" uniqKey="Otter J" first="J. A." last="Otter">J. A. Otter</name>
<name sortKey="Otter, J A" sort="Otter, J A" uniqKey="Otter J" first="J. A." last="Otter">J. A. Otter</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001795 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001795 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Merge |type= RBID |clé= Pascal:14-0118111 |texte= Evaluating the virucidal efficacy of hydrogen peroxide vapour }}
This area was generated with Dilib version V0.6.33. |